Δημοσιεύσεις
Δημοσιεύσεις
Naoum, Panagiota; Athanasakis, Kostas; Kyriopoulos, Ilias; Liapikou, Adamantia; Toumbis, Michail; Kyriopoulos, John
Community acquired pneumonia: a cost-of-illness analysis in Greece Journal Article
In: Rural Remote Health, vol. 20, no. 2, pp. 5400, 2020.
Abstract | BibTeX | Ετικέτες: Greece; community acquired pneumonia; cost of illness; economic burden; CAP
@article{Naoum2020-ef,
title = {Community acquired pneumonia: a cost-of-illness analysis in
Greece},
author = {Panagiota Naoum and Kostas Athanasakis and Ilias Kyriopoulos and Adamantia Liapikou and Michail Toumbis and John Kyriopoulos},
year = {2020},
date = {2020-06-01},
journal = {Rural Remote Health},
volume = {20},
number = {2},
pages = {5400},
address = {Australia},
abstract = {INTRODUCTION: Community acquired pneumonia (CAP) is an acute
respiratory infection with high clinical and economic burden,
especially when hospitalisation is required. The present study
aimed to assess the mean direct cost per CAP outpatient and
inpatient care in Greece, in the absence of previous estimates.
METHODS: A retrospective analysis of patients at a tertiary
hospital, treated between October 2015 and March 2016, was
conducted. Resource use data for inpatients and outpatients were
collected (diagnostic tests, medication, physician visits and
length of hospitalisation, where applicable). Cost calculations
followed a third party payer perspective. Additionally, two
regression models were employed to identify the determinants of
hospitalisation and the main drivers of inpatient and outpatient
cost. RESULTS: Overall, 149 inpatients and 100 outpatients were
included in the analysis. Mean hospitalisation duration was 11.35 days (standard deviation (SD)=9.71 days). Mean direct cost per patient was €110.64 (SD=€58.23) and €7406.56 (SD=€12,124.93) for
outpatient and inpatient cases respectively. (At the time period
for the study, €1.00 was approximately A$1.50.) The main
inpatient cost driver was hospitalisation (94.97%), followed by
medication (3.30%) and diagnostic tests (0.87%). For
outpatients, key cost drivers, in order of magnitude, were
prescribed medication (38.84%), diagnostic tests (33.51%) and
physician visits (17.54%). The regression analyses showed that
the probability of hospitalisation increases with age and number
of symptoms, whereas average cost is mainly influenced by gender,
duration and number of symptoms, and the presence of
comorbidities. CONCLUSION: The results indicate that, in Greece,
CAP is accompanied by a significant economic burden, mainly
attributable to hospitalisation. Interventions toward reducing
the influence of contributors to the incidence and probability of
hospitalisation are essential from a clinical and policy
perspective. Also, the association of symptoms - in terms of
number and duration - and age with hospitalisation probability
and costs highlights that special attention should be given to
the high risk groups of the population, such as the elderly and
the rural residents, both in terms of preventive and therapeutic
services.},
keywords = {Greece; community acquired pneumonia; cost of illness; economic burden; CAP},
pubstate = {published},
tppubtype = {article}
}